Pfizer Inc. and Geron Corporation: SG&A Spending Patterns Compared

A Tale of Two Giants: SG&A Spending in the Pharmaceutical Industry

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry leaders is crucial. Pfizer Inc., a titan in the sector, has consistently demonstrated robust spending on Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Pfizer's SG&A expenses have hovered around $14 billion annually, reflecting its commitment to maintaining a strong market presence and operational efficiency.

In contrast, Geron Corporation, a smaller player, has shown a remarkable growth trajectory in its SG&A spending. Starting at approximately $17 million in 2014, Geron's expenses surged by over 300% to nearly $69 million by 2023. This increase underscores Geron's strategic investments in expanding its market reach and operational capabilities.

This comparison highlights the diverse financial strategies within the pharmaceutical industry, where scale and growth ambitions shape spending patterns.